Skip to main content
. 2007 Jan 31;8(9):649–658. doi: 10.1111/j.1524-6175.2006.05689.x

Table I.

Selected Baseline Characteristics of Angioedema Participants Assigned to Lisinopril vs Those Assigned to the Non‐Lisinopril Treatment Groups

Participants With Angioedema* Participants Without Angioedema
Assigned Treatment Group
Baseline characteristics Lisinopril Non‐lisinopril Total Total
Number 37 16 53 42,365
Angioedema cohort, % 69.81 30.19 100.00
ALLHAT cohort, % 0.087 0.038 0.12 99.88
Age, mean (SD), y 66.6 (8.35) 65.1 (6.81) 66.2 (7.88) 66.9 (7.72)
Age group, n (%), y
55–65 19 (51.35) 9 (56.25) 28 (52.83) 20,099 (47.44)
66–75 11 (29.73) 7 (43.75) 18 (33.96) 16,182 (38.20)
Women, n (%) 13 (35.14) 8 (50.00) 21 (39.62) 19,820 (46.78)
Race, n (%)
Black 23 (62.16) 6 (37.50) 29 (54.72) 15,055 (35.54)
Nonblack 14 (37.84) 10 (62.50) 24 (45.28) 27,309 (64.46)
On blood pressure treatment ≥2 mo 31 (83.78) 14 (87.50) 45 (84.91) 36,791 (86.84)
On blood pressure treatment <2 mo 3 (8.11) 0 (0.00) 3 (5.66) 1425 (3.36)
Untreated at baseline 3 (8.11) 2 (12.50) 5 (9.43) 4148 (9.79)
Current smoker 14 (37.84) 5 (31.25) 19 (35.85) 9250 (21.84)
History of diabetes 4 (10.81) 2 (12.50) 6 (11.32) 15,277 (36.06)
History of CHD 10 (27.03) 6 (37.50) 16 (30.19) 10,750 (25.37)
Aspirin use§ 14 (37.84) 5 (31.25) 19 (35.85) 15,204 (35.89)
Estrogen use (women) 9 (69.23) 1 (12.5) 10 (47.62) 3491 (17.59)
Visit 1 blood pressure, mean (SD)
 Treated ≥2 mo
SBP, mm Hg 139.3 (15.71) 142.0 (10.65) 140.2 (14.26) 142.7 (12.96)
DBP, mm Hg 82.1 (8.10) 84.9 (5.32) 82.9 (7.41) 82.3 (9.52)
Treated <2 mo
SBP, mm Hg 167.3 (7.09) 167.3 (7.09) 158.1 (13.32)
DBP, mm Hg 92.7 (11.24) 92.7 (11.24) 89.4 (9.76)
BMI, mean (SD) (kg/m2) 29.4 (7.61) 29.5 (6.66) 29.4 (7.27) 29.7 (6.15)
Serum potassium, mean (SD) (mEq/dL)§ 4.1 (0.50) 4.1 (0.44) 4.1 (0.47) 4.3 (0.51)
Fasting glucose, mean (SD) (mg/dL) 106.7 (28.72) 121.0 (60.90) 111.2 (41.41) 123.0 (57.06)
Creatinine, mean (SD) (mg/dL)§ 1.08 (0.33) 0.92 (0.13) 1.03 (0.29) 1.02 (0.30)
Total cholesterol, mean (SD) (mg/dL)§ 204.4 (33.27) 220.7 (36.50) 209.4 (34.74) 215.9(43.2)
For each characteristic, 2‐proportion or 2‐sample mean difference tests were performed comparing each of the 3 nondiuretic groups with chlorthalidone, respectively. ALLHAT indicates Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; and BMI, body mass index. *Two participants with angioedema reported open‐label (nonassigned study drug) angiotensin‐converting enzyme inhibitor use: one was assigned to step 1 chlorthalidone and one to step 1 lisinopril. †Comparisons between treatment groups of baseline characteristics among those without angioedema showed no significant differences. ‡Non‐lisinopril treatment groups included chlorthalidone, amlodipine, and doxazosin. §Aspirin use was available for 52 participants; serum potassium, creatinine, and total cholesterol were available for 50 participants; and fasting glucose was available for 41 participants; there were no statistically significant differences (type 1 error probability of .05) between lisinopril and non‐lisinopril groups.